Earnings Releases·Nov 12, 2026, 4:09 PM ET

Arcadia Biosciences — Third Quarter 2026 Earnings Summary

Q3 2026 total revenues rose 24% year-over-year to $1.619 million, while nine-month revenues increased 5% to $4.162 million; Q3 net income improved to $1.755 million ($0.29/share) from $856,000 in 2025, driven by a $2.6 million gain on warrant and option liabilities, though nine-month net loss widened 88% to $8.896 million ($2.39/share).
Operating expenses remained essentially flat in Q3 at $2.458 million but increased 23% to $6.276 million for the first nine months, with nine-month SG&A down $1.4 million due to the absence of M&A expenses, partially offset by a $2.7 million decline in other operating income following a 2025 patent rights gain.
Zola brand revenues hit a record high in Q3 with 24% growth, supported by summer programs securing new 2027 distribution in regions like Texas, alongside the November 2026 launch of a new 1-liter resealable carton espresso formulation.
The company requires additional funding to continue operations with no assurance of availability on reasonable terms and may pursue equity, debt, or strategic alternatives that could result in material dilution to stockholders.